A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel, Multi-Centre, Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects with Moderate to Severe Submental Fat

Clicks: 1
ID: 319694
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #70 of 72 articles by views in Aesthetic surgery journal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Submental fat (SMF) is commonly treated with liposuction, surgery, or injectable drugs. Cholic acid, a primary bile acid, can induce lipolysis. OBJECTIVES: To evaluate the efficacy and safety of MT921, an injectable cholic acid formulation, for reducing moderate to severe SMF. METHODS: Subjects with moderate to severe SMF were randomized to receive MT921 1.0%/1.0 cm, MT921 1.5%/1.0 cm, MT921 1.5%/1.25 cm, or placebo. Primary endpoints were ≥1- and ≥2-grade improvements in clinician- and patient-assessed SMF Rating Scales at 4 weeks after the final treatment. Secondary endpoints included changes in SMFRS, patient satisfaction, Patient-Assessed Submental Fat Impact Scale, and SMF volume or thickness measured by MRI or calipers. Safety was assessed by adverse events, laboratory tests, and vital signs. RESULTS: In groups 1, 2, 3, and 4, respectively, ≥1-grade improvement in clinician-assessed SMFRS was achieved by 72.73%, 88.64%, 79.07%, and 48.78% of subjects, and ≥1-grade improvement in patient-assessed SMFRS by 77.27%, 88.64%, 79.07%, and 46.34%. Compared with placebo, MT921 showed favorable improvements in SMFRS responses, patient satisfaction, PA-SMFIS, and caliper-measured SMF thickness. MRI-measured SMF volume decreased in MT921-treated groups but not in the placebo group. Adverse events were more frequent with MT921 but were mostly mild or moderate. CONCLUSIONS: MT921 showed favorable efficacy signals for reducing moderate to severe SMF and was generally well tolerated. These findings support further evaluation of MT921, particularly the 1.5% formulation, in larger phase 3 trials with longer follow-up.
Reference Key
openalex_W7167417595 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Si‐Hyung Lee, Woo Shun Lee, Min Kyung Shin, Bark‐Lynn Lew, Sang Eun Lee, Ju Hee Lee, Y N Lee, Byung-Sun Kim, D J Kim, Dong Soo Yu, Weon Ju Lee, Gwang Seong Choi
Journal Aesthetic surgery journal
Year 2026
DOI
10.1093/asj/sjag136
URL
https://doi.org/10.1093/asj/sjag136
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.